<DOC>
	<DOCNO>NCT00028730</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total body irradiation donor bone marrow transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin remove T cell donor cell transplant may stop happen . PURPOSE : This phase II trial study well total-body irradiation chemotherapy follow T-cell deplete donor bone marrow transplant work treat young patient hematologic cancer .</brief_summary>
	<brief_title>Total-Body Irradiation Chemotherapy Followed By Donor Bone Marrow Transplant Treating Young Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy hyperfractionated total body irradiation , thiotepa , cyclophosphamide follow T-cell-depleted allogeneic bone marrow transplantation child acute myeloid leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , non-Hodgkin 's lymphoma , myelodysplastic syndrome . - Correlate progenitor cell dose dose clonable T cell incidence quality engraftment , extent chimerism , incidence severity acute chronic graft-versus-host disease , characteristic hematopoietic immunologic reconstitution , overall disease-free survival 2 year patient treat regimen . OUTLINE : Patients undergo total body irradiation three time daily day -9 -7 twice day -6 . Patients receive thiotepa IV 4 hour day -5 -4 cyclophosphamide IV 30 minute day -3 -2 . Patients receive cyclophosphamide , due prior hemorrhagic cystitis exposure high-dose cyclophosphamide ifosfamide , receive fludarabine IV 30 minute day -5 -1 . Patients plan receive family member HLA-mismatched unrelated bone marrow transplantation receive horse anti-thymocyte globulin IV daily day -5 -4 . Patients undergo allogeneic T-cell-depleted bone marrow transplantation day 0 . Patients receive filgrastim ( G-CSF ) IV every 12 hour begin day 7 continue blood count recover . Patients follow every 2-4 week first 100 day post-transplantation , every 6 week 6 month , every 3 month 1 year , every 3-6 month 2 year post-transplantation . PROJECTED ACCRUAL : A total 50 patient ( 25 HLA 6/6 antigen-matched related donor 25 HLA 5/6 antigen-matched related donor HLA 5/6 6/6 antigen-matched unrelated donor ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically confirm goodrisk acute myeloid leukemia ( AML ) first remission HLAcompatible related donor Ineligible unrelated bone marrow transplantation unless fail firstline induction chemotherapy molecular evidence disease time transplantation Histologically confirm highrisk AML first remission High risk define cytogenetics , biphenotypic undifferentiated leukemia phenotype , secondary AML , AML myelodysplastic syndrome ( MDS ) Eligible relate unrelated donor transplantation Histologically confirm acute lymphoblastic leukemia ( ALL ) lymphoblastic lymphoma ( LL ) first remission high risk relapse second third remission High risk relapse define hypodiploidy , pseudodiploidy translocation ( 9 ; 22 ) infant ( 4 ; 11 ) , failure achieve remission four week induction therapy Eligible relate unrelated donor transplantation Histologically confirm chronic myelogenous leukemia ( CML ) least first chronic phase acceleration HLAcompatible related donor Histologically confirm CML first chronic phase fail conventional therapy least second chronic phase acceleration HLAcompatible unrelated donor Histologically confirm nonHodgkin 's lymphoma beyond first complete remission primary induction failure tumor chemosensitive define least 50 % reduction mass size Eligible relate unrelated donor transplantation Histologically confirm MDS intermediate highrisk disease define International Prognostic Scoring System paroxysmal nocturnal hematuria Eligible related unrelated donor transplantation Treatmentrelated MDS leukemia allow primary malignancy ( e.g. , neuroblastoma Ewing 's sarcoma ) low risk recurrence No AML , ALL , LL relapse great third remission No CML blast crisis define 30 % blast plus promyelocytes No active CNS involvement History leukemia cutis allow HLA compatible donor available 5/6 6/6 HLA antigen match related unrelated PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % OR Lansky 50100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) AST great 3 time ULN ( unless liver involvement present ) Renal : Creatinine normal OR Creatinine clearance great 60 mL/min Cardiovascular : LVEF least 50 % rest ( le 50 % rest , must increase exercise ) Pulmonary : Asymptomatic prior risk feature OR DLCO great 40 % predict ( correct hemoglobin ) symptomatic Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV I/II negative No uncontrolled viral , bacterial , fungal infection No known hypersensitivity bovine proteins PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characterisitics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy would preclude total body irradiation dose Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>